In this issue:
Atezolizumab + bevacizumab and chemotherapy in NSCLC subgroups
MTV for stratification of TNM in stage IV NSCLC
Prognostic impact of extranodal extension in pN1–N2 lung adenocarcinoma
First-line durvalumab + etoposide/platinum for extensive-stage SCLC
Lung cancer mortality reduced by LDCT screening
Clinicopathological and molecular features and recurrence in resected early-stage EGFR-mutated NSCLC
DASC-21 for assessing best supportive care in geriatric inoperable advanced NSCLC
Association of pleural fluid exposure with survival in MPM
KRAS mutation affects PD-(L)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma
Durvalumab with platinum-pemetrexed for unresectable MPM
Please login below to download this issue (PDF)